These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36627157)

  • 1. MyTPill: study protocol for a cross-over randomised controlled trial comparing novel strategies to monitor antiretroviral adherence among HIV+ prescription opioid users.
    Bischof JJ; Chai P; Mohamed Y; Padappayil R; Merchant RC; Boyer EW; Rosen R; Reyes-Gibby CC; Viamonte M; W Carrico A
    BMJ Open; 2023 Jan; 13(1):e062805. PubMed ID: 36627157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of a customised digital adherence tool on HIV treatment outcomes in young people living with HIV (YPLHIV) in Blantyre, Malawi: a protocol for a randomised controlled trial.
    Msosa TC; Swai I; Sumari-de Boer M; Ngowi K; F Rinke de Wit T; Aarnoutse R; Nliwasa M
    Trials; 2023 Aug; 24(1):535. PubMed ID: 37582823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
    Bardon AR; Dorward J; Sookrajh Y; Sayed F; Quame-Amaglo J; Pillay C; Feutz E; Ngobese H; Simoni JM; Sharma M; Cressey TR; Gandhi M; Lessells R; Moodley P; Naicker N; Naidoo K; Thomas K; Celum C; Abdool Karim S; Garrett N; Drain PK
    BMJ Open; 2021 Oct; 11(10):e050116. PubMed ID: 34610939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
    Gupta SK; Berhe M; Crofoot G; Benson P; Ramgopal M; Sims J; McDonald C; Ruane P; Sanchez WE; Scribner A; Liu SY; VanderVeen LA; Dvory-Sobol H; Rhee MS; Baeten JM; Koenig E
    Lancet HIV; 2023 Jan; 10(1):e15-e23. PubMed ID: 36566079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CombinADO study to assess the impact of a combination intervention strategy on viral suppression, antiretroviral therapy adherence, and retention in HIV care among adolescents and young people living with HIV: protocol for a cluster-randomized controlled trial.
    Mogoba P; Lesosky M; Zerbe A; Falcao J; Mellins CA; Desmond C; Arnaldo C; Kapogiannis B; Myer L; Abrams EJ
    Trials; 2021 Dec; 22(1):956. PubMed ID: 34961567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda.
    Benitez AE; Musinguzi N; Bangsberg DR; Bwana MB; Muzoora C; Hunt PW; Martin JN; Haberer JE; Petersen ML
    J Int AIDS Soc; 2020 Mar; 23(3):e25467. PubMed ID: 32202067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial.
    Naidoo A; Dooley KE; Naidoo K; Padayatchi N; Yende-Zuma N; Perumal R; Dorse G; Boodhram R; Osuala EC
    BMJ Open; 2022 Nov; 12(11):e067765. PubMed ID: 36356989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
    Daar ES; DeJesus E; Ruane P; Crofoot G; Oguchi G; Creticos C; Rockstroh JK; Molina JM; Koenig E; Liu YP; Custodio J; Andreatta K; Graham H; Cheng A; Martin H; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e347-e356. PubMed ID: 29925490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions to improve adherence to antiretroviral therapy in children with HIV infection.
    Bain-Brickley D; Butler LM; Kennedy GE; Rutherford GW
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD009513. PubMed ID: 22161452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.
    Gross R; Ritz J; Hughes MD; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Godfrey C; Wallis CL; Mellors JW; Mudhune VO; Badal-Faesen S; Grinsztejn B; Collier AC
    Lancet Digit Health; 2019 May; 1(1):e26-e34. PubMed ID: 31528850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence and viral suppression in people living with HIV: a study protocol for the TENDAI randomised controlled trial.
    Abas M; Mangezi W; Nyamayaro P; Jopling R; Bere T; McKetchnie SM; Goldsmith K; Fitch C; Saruchera E; Muronzie T; Gudyanga D; Barrett BM; Chibanda D; Hakim J; Safren SA; O'Cleirigh C
    BMJ Open; 2022 Dec; 12(12):e057844. PubMed ID: 36576191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive STEPS - a randomized controlled efficacy trial of an adaptive intervention for strengthening adherence to antiretroviral HIV treatment among youth: study protocol.
    Mimiaga MJ; Kuhns LM; Biello KB; Olson J; Hoehnle S; Santostefano CM; Hughto JMW; Safi H; Salhaney P; Chen D; Garofalo R
    BMC Public Health; 2018 Jul; 18(1):867. PubMed ID: 30001703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
    Gaur AH; Cotton MF; Rodriguez CA; McGrath EJ; Helström E; Liberty A; Natukunda E; Kosalaraksa P; Chokephaibulkit K; Maxwell H; Wong P; Porter D; Majeed S; Yue MS; Graham H; Martin H; Brainard DM; Pikora C
    Lancet Child Adolesc Health; 2021 Sep; 5(9):642-651. PubMed ID: 34302760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.